Pacific Biosciences Of California (PACB) Operating Expenses (2016 - 2025)
Pacific Biosciences Of California has reported Operating Expenses over the past 16 years, most recently at $57.8 million for Q4 2025.
- Quarterly results put Operating Expenses at $57.8 million for Q4 2025, down 64.58% from a year ago — trailing twelve months through Dec 2025 was $599.6 million (up 17.21% YoY), and the annual figure for FY2025 was $599.6 million, up 17.21%.
- Operating Expenses for Q4 2025 was $57.8 million at Pacific Biosciences Of California, up from $54.8 million in the prior quarter.
- Over the last five years, Operating Expenses for PACB hit a ceiling of $427.6 million in Q1 2025 and a floor of $12.0 million in Q3 2021.
- Median Operating Expenses over the past 5 years was $88.4 million (2022), compared with a mean of $102.3 million.
- Biggest five-year swings in Operating Expenses: soared 634.72% in 2022 and later tumbled 67.25% in 2025.
- Pacific Biosciences Of California's Operating Expenses stood at $81.4 million in 2021, then rose by 13.24% to $92.2 million in 2022, then rose by 5.31% to $97.1 million in 2023, then surged by 67.92% to $163.1 million in 2024, then tumbled by 64.58% to $57.8 million in 2025.
- The last three reported values for Operating Expenses were $57.8 million (Q4 2025), $54.8 million (Q3 2025), and $59.5 million (Q2 2025) per Business Quant data.